Actionable news
0
All posts from Actionable news
Actionable news in LCI: LANNETT COMPANY Inc,

Lannett Announces Receipt Of FDA Acceptable Filing Letter For Fentanyl Patch ANDA

PHILADELPHIA, July 20, 2016 /PRNewswire/ -- Lannett Company, Inc. (LCI) today announced that its strategic partner, Sparsha Pharma USA, Inc., has received an Acceptable for Filing letter from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Fentanyl Transdermal System, 12 mcg/hour, 25 mcg/hour, 50 mcg/hour, 75 mcg/hour and 100 mcg/hour, the generic equivalent of Ortho McNeil's chronic pain treatment Duragesic®. According to IMS, total U.S. sales in 2015 of Fentanyl Transdermal System products at Average Wholesale Price (AWP) were more than $650 million.

"Expanding our pain management franchise is a key component of our growth strategy," said Arthur Bedrosian, chief executive officer of Lannett. "Under the agreement, Sparsha Pharma USA will manufacture the product and Lannett will be responsible for...


More